Safety and Efficacy of Sequential Chemoimmunotherapy Followed by Concurrent Chemoradiation in Unresectable Stage III NSCLC
ID-chemo-ICI followed by cCRT seems feasible and safe for unresectable stage III NSCLC, particularly for patients unsuitable for upfront cCRT. Larger prospective trials are needed to validate these findings and optimize patient selection.
Authors
- Sean S. Park (ORCID: https://orcid.org/0000-0003-3814-853X)
- Dawn Owen
- Konstantinos Leventakos (ORCID: https://orcid.org/0000-0001-9784-8603)
- Arthi Sridhar (ORCID: https://orcid.org/0000-0002-8139-3322)
- Scott L. Hansen (ORCID: https://orcid.org/0000-0002-0162-0901)
- Julian R. Molina (ORCID: https://orcid.org/0000-0002-9962-4635)
- Katherine E. Smith (ORCID: https://orcid.org/0009-0004-5114-794X)
- Aadel A. Chaudhuri (ORCID: https://orcid.org/0000-0003-3115-3061)
- Aaron S. Mansfield (ORCID: https://orcid.org/0000-0002-9483-6903)
- Mohamed Shanshal (ORCID: https://orcid.org/0009-0005-0775-2680)
- Anastasios Dimou (ORCID: https://orcid.org/0000-0002-3950-3305)
- Sydney Pulsipher
- Kenneth W. Merrell (ORCID: https://orcid.org/0000-0002-3831-5644)
- Yolanda I. Garces (ORCID: https://orcid.org/0000-0002-9170-3849)
- Aditi P. Singh (ORCID: https://orcid.org/0000-0002-2063-6407)
- Kaushal Parikh (ORCID: https://orcid.org/0000-0001-6759-9351)
- Kenneth R. Olivier
Institutions
- Mayo Clinic (US)
- WinnMed (US)
Publication Details
- Journal
- JTO Clinical and Research Reports
- Published
- 2025-08-22
- DOI
- https://doi.org/10.1016/j.jtocrr.2025.100890
- Primary Topic
- Lung Cancer Treatments and Mutations
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Mayo Foundation for Medical Education and Research